[Influence of initial protocolized treatment with steroids in length of stay and costs of community acquired pneumonia]

Rev Esp Quimioter. 2017 Oct;30(5):350-354. Epub 2017 Jul 24.
[Article in Spanish]

Abstract

Objective: The aim of the study was to analyze the impact of steroid treatment in patients with community acquired pneumonia (CAP), both in length of stay and economical cost of admission at a clinical university hospital.

Methods: Prospective study of admitted patients with the diagnosis of CAP, both in Internal Medicine and Infectious diseases department. The study was conducted from January to march 2015; patients receiving steroids from diagnosis to end of antibiotic treatment were classified as group I; otherwise, they were considered in group II. Administration of steroids was done according to the criteria of the responsible. Cost was stablished according to CAP Diagnostic Related Group (DRG).

Results: Prevalence of patients younger than 65 year-old was higher in group I (p<0.05). In bivariate analyses, mean admission time was lower in group I (5.37 vs 8.88 days) (p<0.0005) and also economical cost (2,361 euros vs 3,907 euros) (p<0.0005). In multivariate analysis, factors independently associated to higher cost (>3,520 euros) were COPD (OR=2.602; 95% CI 1.074-6.305) and group II (patients with no steroids) (OR=6.2; p=0,007).

Conclusions: No administration of steroids in patients with CAP was associated, together with COPD, with higher economical cost (evaluated by DRG/length of stay).

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use
  • Clinical Protocols
  • Community-Acquired Infections / drug therapy*
  • Community-Acquired Infections / economics*
  • Community-Acquired Infections / epidemiology
  • Costs and Cost Analysis
  • Female
  • Humans
  • Length of Stay
  • Male
  • Middle Aged
  • Pneumonia / drug therapy*
  • Pneumonia / economics*
  • Pneumonia / epidemiology
  • Prevalence
  • Prospective Studies
  • Pulmonary Disease, Chronic Obstructive / complications
  • Pulmonary Disease, Chronic Obstructive / drug therapy
  • Pulmonary Disease, Chronic Obstructive / economics
  • Spain / epidemiology
  • Steroids / economics*
  • Steroids / therapeutic use*

Substances

  • Anti-Bacterial Agents
  • Steroids